Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats

Nawal M. Al-Rasheed, Nouf M. Al-Rasheed, Iman H. Hasan, Maha A. Al-Amin, Hanaa N. Al-Ajmi, Raeesa A. Mohamad, Ayman M. Mahmoud

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

Simvastatin is a lipid-lowering agent used to treat hypercholesterolemia and to reduce the risk of heart disease. This study scrutinized the beneficial effects of simvastatin on experimental diabetic cardiomyopathy (DCM), pointing to the role of hyperglycemia-induced oxidative stress and inflammation. Diabetes was induced by intraperitoneal injection of streptozotocin and both control and diabetic rats received simvastatin for 90 days. Diabetic rats showed significant cardiac hypertrophy, body weight loss, hyperglycemia, and hyperlipidemia. Serum creatine kinase MB (CK-MB) and troponin I showed a significant increase in diabetic rats. Simvastatin significantly improved body weight, attenuated hyperglycemia and hyperlipidemia, and ameliorated CK-MB and troponin I. Simvastatin prevented histological alterations and deposition of collagen in the heart of diabetic animals. Lipid peroxidation and nitric oxide were increased in the heart of diabetic rats whereas antioxidant defenses were decreased. These alterations were significantly reversed by simvastatin. In addition, simvastatin decreased serum inflammatory mediators and expression of NF-κB in the diabetic heart. Cardiac caspase-3 was increased in the diabetic heart and decreased following treatment with simvastatin. In conclusion, our results suggest that simvastatin alleviates DCM by attenuating hyperglycemia/hyperlipidemia-induced oxidative stress, inflammation, and apoptosis.

Original languageEnglish
Article number1092015
JournalOxidative Medicine and Cellular Longevity
Volume2017
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Diabetic Cardiomyopathies
Oxidative stress
Simvastatin
Rats
Oxidative Stress
Inflammation
Hyperglycemia
Hyperlipidemias
MB Form Creatine Kinase
Troponin I
Body Weight
Lipids
Cardiomegaly
Streptozocin
Medical problems
Hypercholesterolemia
Intraperitoneal Injections
Serum
Caspase 3
Lipid Peroxidation

Cite this

Al-Rasheed, Nawal M. ; Al-Rasheed, Nouf M. ; Hasan, Iman H. ; Al-Amin, Maha A. ; Al-Ajmi, Hanaa N. ; Mohamad, Raeesa A. ; Mahmoud, Ayman M. / Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats. In: Oxidative Medicine and Cellular Longevity. 2017 ; Vol. 2017.
@article{c46004835fb44a78b45fc28ba50fac5e,
title = "Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats",
abstract = "Simvastatin is a lipid-lowering agent used to treat hypercholesterolemia and to reduce the risk of heart disease. This study scrutinized the beneficial effects of simvastatin on experimental diabetic cardiomyopathy (DCM), pointing to the role of hyperglycemia-induced oxidative stress and inflammation. Diabetes was induced by intraperitoneal injection of streptozotocin and both control and diabetic rats received simvastatin for 90 days. Diabetic rats showed significant cardiac hypertrophy, body weight loss, hyperglycemia, and hyperlipidemia. Serum creatine kinase MB (CK-MB) and troponin I showed a significant increase in diabetic rats. Simvastatin significantly improved body weight, attenuated hyperglycemia and hyperlipidemia, and ameliorated CK-MB and troponin I. Simvastatin prevented histological alterations and deposition of collagen in the heart of diabetic animals. Lipid peroxidation and nitric oxide were increased in the heart of diabetic rats whereas antioxidant defenses were decreased. These alterations were significantly reversed by simvastatin. In addition, simvastatin decreased serum inflammatory mediators and expression of NF-κB in the diabetic heart. Cardiac caspase-3 was increased in the diabetic heart and decreased following treatment with simvastatin. In conclusion, our results suggest that simvastatin alleviates DCM by attenuating hyperglycemia/hyperlipidemia-induced oxidative stress, inflammation, and apoptosis.",
author = "Al-Rasheed, {Nawal M.} and Al-Rasheed, {Nouf M.} and Hasan, {Iman H.} and Al-Amin, {Maha A.} and Al-Ajmi, {Hanaa N.} and Mohamad, {Raeesa A.} and Mahmoud, {Ayman M.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/1092015",
language = "English",
volume = "2017",
journal = "Oxidative Medicine and Cellular Longevity",
issn = "1942-0900",
publisher = "Hindawi Publishing Corporation",

}

Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats. / Al-Rasheed, Nawal M.; Al-Rasheed, Nouf M.; Hasan, Iman H.; Al-Amin, Maha A.; Al-Ajmi, Hanaa N.; Mohamad, Raeesa A.; Mahmoud, Ayman M.

In: Oxidative Medicine and Cellular Longevity, Vol. 2017, 1092015, 01.01.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats

AU - Al-Rasheed, Nawal M.

AU - Al-Rasheed, Nouf M.

AU - Hasan, Iman H.

AU - Al-Amin, Maha A.

AU - Al-Ajmi, Hanaa N.

AU - Mohamad, Raeesa A.

AU - Mahmoud, Ayman M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Simvastatin is a lipid-lowering agent used to treat hypercholesterolemia and to reduce the risk of heart disease. This study scrutinized the beneficial effects of simvastatin on experimental diabetic cardiomyopathy (DCM), pointing to the role of hyperglycemia-induced oxidative stress and inflammation. Diabetes was induced by intraperitoneal injection of streptozotocin and both control and diabetic rats received simvastatin for 90 days. Diabetic rats showed significant cardiac hypertrophy, body weight loss, hyperglycemia, and hyperlipidemia. Serum creatine kinase MB (CK-MB) and troponin I showed a significant increase in diabetic rats. Simvastatin significantly improved body weight, attenuated hyperglycemia and hyperlipidemia, and ameliorated CK-MB and troponin I. Simvastatin prevented histological alterations and deposition of collagen in the heart of diabetic animals. Lipid peroxidation and nitric oxide were increased in the heart of diabetic rats whereas antioxidant defenses were decreased. These alterations were significantly reversed by simvastatin. In addition, simvastatin decreased serum inflammatory mediators and expression of NF-κB in the diabetic heart. Cardiac caspase-3 was increased in the diabetic heart and decreased following treatment with simvastatin. In conclusion, our results suggest that simvastatin alleviates DCM by attenuating hyperglycemia/hyperlipidemia-induced oxidative stress, inflammation, and apoptosis.

AB - Simvastatin is a lipid-lowering agent used to treat hypercholesterolemia and to reduce the risk of heart disease. This study scrutinized the beneficial effects of simvastatin on experimental diabetic cardiomyopathy (DCM), pointing to the role of hyperglycemia-induced oxidative stress and inflammation. Diabetes was induced by intraperitoneal injection of streptozotocin and both control and diabetic rats received simvastatin for 90 days. Diabetic rats showed significant cardiac hypertrophy, body weight loss, hyperglycemia, and hyperlipidemia. Serum creatine kinase MB (CK-MB) and troponin I showed a significant increase in diabetic rats. Simvastatin significantly improved body weight, attenuated hyperglycemia and hyperlipidemia, and ameliorated CK-MB and troponin I. Simvastatin prevented histological alterations and deposition of collagen in the heart of diabetic animals. Lipid peroxidation and nitric oxide were increased in the heart of diabetic rats whereas antioxidant defenses were decreased. These alterations were significantly reversed by simvastatin. In addition, simvastatin decreased serum inflammatory mediators and expression of NF-κB in the diabetic heart. Cardiac caspase-3 was increased in the diabetic heart and decreased following treatment with simvastatin. In conclusion, our results suggest that simvastatin alleviates DCM by attenuating hyperglycemia/hyperlipidemia-induced oxidative stress, inflammation, and apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=85030645749&partnerID=8YFLogxK

U2 - 10.1155/2017/1092015

DO - 10.1155/2017/1092015

M3 - Article

VL - 2017

JO - Oxidative Medicine and Cellular Longevity

JF - Oxidative Medicine and Cellular Longevity

SN - 1942-0900

M1 - 1092015

ER -